<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290936</url>
  </required_header>
  <id_info>
    <org_study_id>IN-TW-320-5598</org_study_id>
    <nct_id>NCT04290936</nct_id>
  </id_info>
  <brief_title>Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence</brief_title>
  <official_title>Decreasing Risk of Recurrence by TAF in HCC Patients After Curative Treatment With Low HBV Viral Load</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma(HCC) is prevalent in the hepatitis B virus(HBV) infection endemic&#xD;
      areas. For early stage of HCC, surgical resection, radiofrequency ablation (RFA) or microwave&#xD;
      ablation (MWA) are the main treatment options. However, the risk of recurrence is as high as&#xD;
      50% in 5 years by surgical resection or 60-70% in 5 years by RFA. In average, the recurrence&#xD;
      rate of HCC at 2 years is 30%. Many factors are associated with the HCC recurrence, including&#xD;
      HBV viral load, cirrhotic stage, tumor size, tumor number, vascular invasion,&#xD;
      alpha-fetoprotein(AFP) level and so on. Of them, high HBV viral load is associated with the&#xD;
      risk of HCC recurrence after surgical resection, especially on late recurrence. In one&#xD;
      previous randomized controlled trial, patients who received lamivudine, adefovir dipivoxil,&#xD;
      or entecavir had significantly decreased early recurrence of HCC, however, whether&#xD;
      nucleos(t)ide analogues(NUCs) can further reduce the risk of recurrence in patients with low&#xD;
      viral loads (&lt;2000 IU/ml) is still unclear.&#xD;
&#xD;
      In EASL 2017 guideline, all patients with compensated or decompensated cirrhosis need&#xD;
      antiviral treatment, with any detectable HBV DNA level and regardless of alanine&#xD;
      aminotransferase(ALT) levels. In Taiwan, even in chronic hepatitis B(CHB) infection patients&#xD;
      with HCC, NUC is not reimbursed if their HBV viral load was less than 2000 IU/ml. It is an&#xD;
      important unmet medical need to understanding the role of TAF in reducing the risk of&#xD;
      recurrence in HBV-HCC patients with low HBV viral load (HBV DNA&lt;2000 IU/ml) and significant&#xD;
      liver fibrosis after curative treatment (The definition of significant liver fibrosis was&#xD;
      based on reference. In our recent retrospective study, the risk of recurrence and survival&#xD;
      are comparable between patients with and without NUCs treatment before HCC development only&#xD;
      if NUCs treatment can be provided after curative treatment of HCC. However, a higher risk of&#xD;
      recurrence was observed in cirrhotic patients with prior NUCs treatment before HCC&#xD;
      occurrence. It would be interesting to investigate the incidence of recurrence by switching&#xD;
      to tenofovir alafenamide(TAF) after curative treatment of HCC in patients already on NUCs&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1: NUC-naïve patients will be randomization into tenofovir alafenamide(TAF) or placebo arm in 1:1 ratio.&#xD;
Part 2: NUCs-treated patients will be switched to tenofovir alafenamide(TAF) treatment.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Hepatocellular carcinoma(HCC) recurrence</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>Incidence of HCC recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatocellular carcinoma(HCC) recurrence</measure>
    <time_frame>Up to 3 years.</time_frame>
    <description>HCC recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatocellular carcinoma(HCC) recurrence in NUCs-treated patients after switched to TAF treatment</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>HCC recurrence in NUCs-treated patients after switched to TAF treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic (kinetics) changes in the bio-markers related to hepatitis B virus(HBV) infection</measure>
    <time_frame>Up to 3 years.</time_frame>
    <description>HBV DNA, HBsAg, HBV RNA, HBcrAg, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the renal function</measure>
    <time_frame>Up to 3 years.</time_frame>
    <description>eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the bone density</measure>
    <time_frame>Up to 3 years.</time_frame>
    <description>Dual-energy X-ray absorptiometry(DEXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regression of liver fibrosis</measure>
    <time_frame>Up to 3 years.</time_frame>
    <description>Fibroscan</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">402</enrollment>
  <condition>HCC Patients After Curative Treatment With Low HBV Viral Load</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NUC-naïve patients will be randomization into Tenofovir Alafenamide(TAF) treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NUC-naïve patients will be randomization into placebo arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NUCs-treated patients will be switched to Tenofovir Alafenamide(TAF) treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemlidy® (Tenofovir Alafenamide; TAF)</intervention_name>
    <description>Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HBsAg-positive for more than 6 months.&#xD;
&#xD;
          -  HCC after curative treatment (eight by surgical resection or RFA or MWA) with&#xD;
             significant liver fibrosis (either by Ishak≧2, Metavir≧2, Knodell≧3) or cirrhosis and&#xD;
             HBV DNA&lt;2,000 IU/ml.&#xD;
&#xD;
          -  The duration of curative treatment of HCC to study enrollment should be less than 90&#xD;
             days.&#xD;
&#xD;
          -  Curative treatment is confirmed by contrast-enhanced CT or MR after the&#xD;
             surgery/RFA/MWA.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child-Pugh class B8-C.&#xD;
&#xD;
          -  Active EV bleeding within 4 weeks.&#xD;
&#xD;
          -  History of hepatic encephalopathy or intractable ascites.&#xD;
&#xD;
          -  BCLC C or D.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yi-Hsiang Huang, M.D. Ph.D.</last_name>
    <phone>+886-2-28757506</phone>
    <email>yhhuang@vghtpe.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ChiehJu Lee, Master</last_name>
    <phone>+886-939859265</phone>
    <email>ssbugi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <state>State...</state>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <state>State...</state>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chieh-Ju Lee, Master</last_name>
      <phone>+886-939859265</phone>
      <email>ssbugi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chun-Jen Liu, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <state>State...</state>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Hsaing Huang, M.D. Ph.D.</last_name>
      <phone>+886-2-28757506</phone>
      <email>yhhuang@vghtpe.gov.tw</email>
    </contact>
    <contact_backup>
      <last_name>Chieh-Ju Lee, Master</last_name>
      <phone>+886-939859265</phone>
      <email>ssbugi@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yi-Hsiang Huang, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Veterans General Hospital, Taiwan</investigator_affiliation>
    <investigator_full_name>vghtpe user</investigator_full_name>
    <investigator_title>Yi-Hsiang Huang, M.D., Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

